Rockwell Medical, Inc. (RMTI)

NASDAQ: RMTI · USD

$6.70

-0.16 (-2.3%)· Recorded snapshot

Market cap	27M
Revenue (ttm)	69.4M
Net income (ttm)	-5.2M
EPS (ttm)	-$1.36
Shares out	4M
Volume	17,191
Beta	1.63

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 69.4M
Net income (ttm): -5.2M
EPS (ttm): -$1.36
Market cap: 27M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	보유

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-15.5

P25 -113.8P50 -46.5P75 -0.9

ROIC-6.1

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All RMTI indicators

Market & fundamental data

Available fields

231

Groups with data

Currency

USD

Showing 231 of 231 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001041024
Company name	Rockwell Medical, Inc.
Country	United States
Country code	US
CUSIP number	774374409
Earnings date	2026-11-12
Earnings time	bmo
Employees	157
Employees change	-87
Employees growth	-35.66%
Enterprise value	$16.1M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1994
Industry	Drug Manufacturers - Specialty & Generic
IPO date	1998-01-27
Is primary listing	Yes
Is SPAC	No
ISIN number	US7743744093
Last 10-K release date	2026-03-26
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split date	2026-07-01
Last stock split type	Reverse
Market cap	$27M
Market cap category	Nano-Cap
Next earnings date	2026-11-12
Options	Yes
Price	$6.70
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	RMTI
U.S. state	Michigan
Website	https://www.rockwellmed.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-20.25%
EV/FCF	10.9x
EV/Sales	0.24x
FCF / EV yield	9.17%
FCF yield	5.57%
Forward EV/Sales	0.22x
Forward P/S	0.37x
Industry forward P/E	13.59x
Industry P/E	175.96x
P/(OCF - SBC) ratio	26.95x
P/B ratio	0.78x
P/FCF ratio	17.95x
P/OCF ratio	9.54x
P/S ratio	0.4x
Price / tangible book value	1.12x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-6.52%
EBITDA margin	-3.5%
FCF margin	2.22%
Gross margin	17.71%
Operating margin	-6.52%
Pretax margin	-7.33%
Profit margin	-7.33%
Profit per employee	$-33,369
Revenue per employee	$441,968
ROA	-5.18%
ROA (5Y)	-12.97%
ROCE	-9.97%
ROE	-15.53%
ROE (5Y)	-93.45%
ROIC	-6.05%
SBC / revenue	2.7%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	0
FCF growth	-42.62%
FCF growth (Q)	-12.92%
Gross profit growth	-20.27%
Gross profit growth (Q)	29.56%
Gross profit growth 3Y	22.12%
Gross profit growth 5Y	69.79%
Net income growth quarters	1
Net income growth years	0
OCF growth	-17.16%
OCF growth (Q)	12.8%
Revenue growth	-21.12%
Revenue growth (Q)	10.63%
Revenue growth (QoQ)	2.56%
Revenue growth 10Y	2.24%
Revenue growth 3Y	-2.88%
Revenue growth 5Y	2.59%
Revenue growth quarters	1
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-1.4M
Depreciation and amortization	$2.1M
EBIT	$-4.5M
EBITDA	$-2.4M
EPS	$-1.36
FCF per share	$0.38
Financing cash flow	$4.2M
Free cash flow	$1.5M
Free cash flow minus SBC	$-331,000
Gross profit	$12.3M
Investing cash flow	$-9M
Net borrowing	$-1.1M
Net cash flow	$-2M
Net income	$-5.2M
Operating cash flow minus SBC	$1M
Operating income	$-4.5M
Revenue	$69.4M
Stock-based compensation	$1.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-7.5
Book value per share	$8.83
Debt / EBITDA	6,966.5
Debt / equity	0.4
Debt / FCF	9.05
Goodwill	$920,000
Interest coverage	-3.99
Long-term assets	$20.2M
Long-term liabilities	$10.3M
Net cash (debt)	$10.9M
Net cash / market cap	39.29%
Net cash growth	146.07%
Net debt / equity	-0.31
Net debt / FCF	-7.05
Piotroski F-Score	5
Property, plant and equipment	$9.3M
Shareholders' equity	$35.1M
Tangible book value	$24.8M
Tangible book value per share	$6.24
Total assets	$56.5M
Total cash	$24.8M
Total debt	$13.9M
Total liabilities	$21.4M
WACC	10.94%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	1.27
Current assets	$36.4M
Current liabilities	$11.2M
Current ratio	3.25
Inventory turnover	16.37
Net working capital	$4.1M
Quick ratio	2.96
Working capital	$25.2M
Working capital turnover	3.03

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-16.28%
Dividend yield	0%
Shareholder yield	-16.28%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-98.87%
10Y return CAGR	-36.15%
10Y total return	-98.87%
150-day SMA	$7.64
15Y price change	-99.19%
15Y return CAGR	-27.46%
15Y total return	-99.19%
1D price change	-2.33%
1M price change	-15.11%
1M total return	-15.11%
1W price change	-1.73%
1W total return	-1.73%
1Y price change	-37.68%
1Y return CAGR	-37.7%
1Y total return	-37.68%
20-day SMA	$7.62
200-day SMA	$8.26
20Y price change	-99.11%
20Y return CAGR	-21.02%
20Y total return	-99.11%
3M price change	1.5%
3M total return	1.5%
3Y price change	-57.46%
3Y return CAGR	-24.78%
3Y total return	-57.46%
50-day SMA	$7.92
50-day SMA vs 200-day SMA	50under200
52-week high	$12.90
52-week high date	2026-01-21
52-week low	$4.89
52-week low date	2026-07-02
5Y price change	-87.8%
5Y return CAGR	-34.34%
5Y total return	-87.8%
6M price change	-15.99%
6M total return	-15.99%
All-time high	$2,078.99
All-time high date	2015-07-17
All-time low	$4.89
All-time low date	2026-07-02
Average true range (ATR)	$0.44
Average volume	28.6K
Beta (1Y)	0.47
Beta (2Y)	1.11
Beta (5Y)	1.63
Change from 52-week high	-48.06%
Change from 52-week low	37.16%
Change from all-time high	-99.66%
Change from all-time low	45.45%
Change from open	-0.45%
Day's gap	-1.9%
Dollar volume	$115,180
High price	$6.73
Low price	$6.70
Monthly RSI	40.08
Open price	$6.73
Position in 52-week range	0%
Previous close	$6.86
Price vs 150-day SMA	-6.99%
Price vs 20-day SMA	-6.81%
Price vs 200-day SMA	-13.95%
Price vs 50-day SMA	-10.32%
Relative volume	0.6
RSI	40.75
Sharpe ratio	-0.43
Sharpe ratio (3Y)	-0.05
Sharpe ratio (5Y)	-0.09
Sortino ratio	-0.59
Sortino ratio (3Y)	0
Sortino ratio (5Y)	-0.07
Volume	17.2K
Weekly RSI	42.48
YTD price change	-14.76%
YTD total return	-14.76%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	3.6M
Float percentage	88.97%
Shares change (QoQ)	0.42%
Shares change (YoY)	16.28%
Shares held by insiders	2.13%
Shares held by institutions	12.96%
Shares outstanding	4M
Short % of float	1.95%
Short % of shares	1.74%
Short ratio	3.3 days

Deeper analysis on RMTI

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this RMTI report

Is a complete RMTI research report available?

No complete published report is available for Rockwell Medical, Inc. (RMTI) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Rockwell Medical, Inc. (RMTI)

Price

Financial snapshot

Fair-value bridge

Latest news · RMTI

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All RMTI indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on RMTI

Frequently asked questions